J-Pharma Co.,Ltd

A biotech startup dedicated to exploring the untapped potential of SLC transporters and developing innovative therapies that address unmet medical needs, contributing to better health and renewed hope for people around the world.

Biliary tract cancer is a condition in which approximately 20,000 new cases are diagnosed each year in Japan and, separately, across five European countries (the United Kingdom, France, Germany, Italy and Spain), and around 14,000 new cases are diagnosed annually in the United States. Because symptoms are often minimal or absent in the early stages, many patients are not diagnosed until the disease has reached an advanced stage. Treatment options for advanced biliary tract cancer remain extremely limited, and the five-year survival rate is below 25%, making it one of the cancers with the poorest prognosis, second only to pancreatic cancer. Against this backdrop, biliary tract cancer represents a major area of unmet medical need, and there is a strong demand for the development of novel therapies.
In biliary tract cancer, when patient cohorts were compared according to LAT1 expression levels, the high-LAT1-expression group was confirmed to have a significantly shorter survival time. These findings indicate that high LAT1 expression may serve as a prognostic biomarker in patients with biliary tract cancer, and provide a rationale for the growing recognition of LAT1 as a promising candidate for new molecularly targeted therapies.
J-Pharma’s LAT1 inhibitor, Nanvuranlat, has also demonstrated a favourable safety profile, and therefore holds the potential to be a treatment that is not only effective but also gentler on patients—one that can better support them throughout their treatment journey.

1. Revolutionizing Healthcare by pioneering trustworthy medical standards. We invest in products and services that redefine healthcare’s reliability and trustworthiness, fostering behavioral change among providers.
2.  Empowering Holistic Well-Being by inspiring positive lifestyle and activity choices.We invest in products and services that motivate individuals towards health-positive decisions, emphasizing the critical role of consumer behavior in wellness.